Logo for LENZ Therapeutics Inc

LENZ Therapeutics Investor Relations Material

Latest events

Logo for LENZ Therapeutics Inc

Q3 2024

LENZ Therapeutics
Logo for LENZ Therapeutics

Q3 2024

6 Nov, 2024
Logo for LENZ Therapeutics

Q2 2024

14 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from LENZ Therapeutics Inc

Access all reports
LENZ Therapeutics Inc. is a biopharmaceutical company that specializes in the development and commercialization of innovative ophthalmic therapies aimed at improving vision. The company's primary focus is on treating presbyopia, a common age-related condition that affects near vision. LENZ Therapeutics is currently advancing its lead product candidates, LNZ100 and LNZ101, which are in Phase III clinical trials. These products are aceclidine-based eye drops designed to restore near vision for individuals with presbyopia. The company is headquartered in Del Mar, California, and its shares are listed on the NASDAQ.